Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats
- 1 June 2014
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 60 (6) , 1135-1142
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effectsJournal of Hepatology, 2012
- Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ –Knockout (CM-PGKO) MicePLOS ONE, 2012
- Pioglitazone Attenuates Vascular Fibrosis in Spontaneously Hypertensive RatsPPAR Research, 2012
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Management of Varices and Variceal Hemorrhage in CirrhosisNew England Journal of Medicine, 2010
- Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosisBritish Journal of Pharmacology, 2009
- Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats†Hepatology, 2007
- Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseHepatology, 2007
- NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive ratsGut, 2006
- Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive ratsJournal of Hepatology, 2005